Endometrial cancer is the most common gynecologic cancer in the United States and it contributes to the second most gynecologic cancer-related deaths. With upfront surgery, the specific characteristics of both the patient and tumor allow for risk-tailored treatment algorithms including adjuvant radiotherapy and systemic therapy. In this narrative review, we discuss the current radiation treatment paradigm for endometrial cancer with an emphasis on various radiotherapy modalities, techniques, and dosing regimens. We then elaborate on how to tailor radiotherapy treatment courses in combination with other cancer-directed treatments, including chemotherapy and immunotherapy. In conclusion, this review summarizes ongoing research that aims to further individualize radiotherapy regimens for individuals in an attempt to improve patient outcomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11011021 | PMC |
| http://dx.doi.org/10.3390/cancers16071346 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
POLE mutations in endometrial carcinoma: Clinical and genomic landscape from a large prospective single-center cohort.
Cancer
February 2025
Departmental Unit of Molecular and Genomic Diagnostics, Genomics Core Facility, G-STeP, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Background: To date, 11 DNA polymerase epsilon (POLE) pathogenic variants have been declared "hotspot" mutations. Patients with endometrial cancer (EC) characterized by POLE hotspot mutations (POLEmut) have exceptional survival outcomes. Whereas international guidelines encourage deescalation of adjuvant treatment in early-stage POLEmut EC, data regarding safety in POLEmut patients with unfavorable characteristics are still under investigation.
View Article and Find Full Text PDFMeta-analysis of the ability of mutational profiles on the cancer genome atlas to predict prognosis in endometrial carcinoma.
Int J Gynaecol Obstet
January 2025
Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu, People's Republic of China.
Background: In 2013, The Cancer Genome Atlas Research Network suggested that endometrial carcinoma patients may be reclassified into four molecular prognostic groups.
Objective: To compare survival of endometrial carcinoma patients with different mutational profiles.
Search Strategy: Studies reporting survival of endometrial carcinoma patients were identified through systematic searches of four databases.
Potential value of novel multiparametric MRI radiomics for preoperative prediction of microsatellite instability and Ki-67 expression in endometrial cancer.
Sci Rep
January 2025
Department of Oncology, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, China.
Exploring the potential of advanced artificial intelligence technology in predicting microsatellite instability (MSI) and Ki-67 expression of endometrial cancer (EC) is highly significant. This study aimed to develop a novel hybrid radiomics approach integrating multiparametric magnetic resonance imaging (MRI), deep learning, and multichannel image analysis for predicting MSI and Ki-67 status. A retrospective study included 156 EC patients who were subsequently categorized into MSI and Ki-67 groups.
View Article and Find Full Text PDFComprehensive pan-cancer analysis reveals NTN1 as an immune infiltrate risk factor and its potential prognostic value in SKCM.
Sci Rep
January 2025
The First Affiliated Hospital of Zhengzhou University, No.1 Jianshe Road, Zhengzhou, 450052, Henan, China.
Netrin-1 (NTN1) is a laminin-related secreted protein involved in axon guidance and cell migration. Previous research has established a significant connection between NTN1 and nervous system development. In recent years, mounting evidence indicates that NTN1 also plays a crucial role in tumorigenesis and tumor progression.
View Article and Find Full Text PDF[Pilomatrix-like high-grade endometrioid carcinoma of the ovary: report of two cases].
Zhonghua Bing Li Xue Za Zhi
February 2025
Department of Pathology, the Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014, China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!